002166 莱茵生物
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入1,272,1568.73%1,771,7601,493,9301,400,7371,053,235
减:营业总成本1,186,42612.41%1,555,7351,406,2181,176,598933,946
    其中:营业成本954,10113.51%1,252,1861,129,188969,329739,325
               财务费用27,3089.96%30,93724,4297,85825,425
               资产减值损失(569)-184.59%(21,463)(44,290)(23,262)(6,161)
公允价值变动收益4,377-166.22%2,02545,34836,80812,541
投资收益4,606-35.84%7,1794,8282,7764,437
    其中:对联营企业和合营企业的投资收益------------
营业利润106,582-20.53%213,428118,321253,690151,954
利润总额104,930-17.86%207,837116,363238,336151,937
减:所得税费用25,73818.46%40,66318,01750,04420,752
净利润79,192-25.30%167,17498,346188,292131,185
减:非控股权益8,797100.19%4,16515,8359,55512,747
股东净利润70,395-30.73%163,00982,511178,738118,438

市场价值指针
每股收益 (元) *0.100-28.57%0.2200.1100.2900.210
每股派息 (元) *----0.1000.2000.100--
每股净资产 (元) *4.1481.26%4.2104.2204.1303.306
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容